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Sunmmary Previous reports have indicated that reconstituted basement membrane (matrigel), when co-injected
with either established or primary human tumour cells, can improve the growth of subcutaneous xenografts in
nude mice. The human adenocarcinoma cell lines A549, SW480, and WiDr, and the human fibrosarcoma cell
line HT1080scc2 exhibit varying degrees of tumourigenicity in nude mice. All these lines showed increased
tumourigenicity and/or growth rate, together with a change towards a more differentiated tissue morphology,
when co-injected with matrigel into nude mice. Experiments using A549 cell line have indicated that the effect
of matrigel is concentration-dependent and that increased growth rate is not maintained when xenografts
grown with matrigel are passaged into further mice. These results strongly suggest that increased tumour
growth results from the improved growth conditions afforded by matrigel, rather than from the selection of
subpopulations of the most tumourigenic cells. Increased growth of intracaecal tumours arising from the
co-injection of SW480 cells with matrigel, indicate a possible use for matrigel in the development of more
relevant animal models using the orthotopic site. Purified laminin significantly increased the growth of sc
tumours resultant from co-injection with either WiDr or A549 cells, whereas collagen IV or laminin with
entactin showed no such effect. A role for free laminin in the stimulation of cell growth in the absence of an
intact basement membrane is discussed.
Many established models of anti-tumour chemotherapy are
based upon the successful propagation of established cell
lines of human origin as subcutaneous xenografts in athymic
nude mice. Only a small minority of these cell lines however
exhibit the tumourigenicity and growth rates which permit
their use in such assays. The success rate of lines established
in vivo from human tumours can be as low as 44% for
colorectal and 10% in the case of breast (Sordat & Wang,
1984). Consistent xenograft growth is important when
attempting to minimise variation within groups both to
satisfy the requirements of the experiment and also the
demands of the Animals (Scientific Procedures) Act 1986 as
outlined by Workman et al. (1988). One possible way of
improving such assay systems is in the use of basement
membrane components.
The structure and functions of basement membrane and its
constitutive proteins, together with its interaction with
tumour cells, have been the subject of detailed investigations
in vitro (Liotta et al., 1986; Yurchenko & Schittny, 1990).
Matrigel is a solubilised tissue basement membrane prepara-
tion extracted from the Engelbreth-Holm-Swarm murine
tumour. Matrigel is composed of laminin, collagen type IV,
heparin sulphate proteoglycan and entactin, along with
TGF, and other growth factors which occur in the EHS
tumour. Co-transplantation with matrigel has been found to
enhance the growth of a range of cells in vivo including small
cell lung carcinoma (SCLC), human prostatic carcinoma and
human breast adenocarcinoma MCF-7 (Fridman et al., 1990;
Pretlow et al., 1991; Noel et al., 1992).
In this study, we present evidence of the tumour-enhancing
properties ofmatrigel on a panel of four cell lines selected for
their varied growth properties in vivo, together with observa-
tions on the concentration dependence and non-sustainability
of the observed effects on subsequent passage. Of the two
colon adenocarcinoma lines selected, SW480 is reported to be
non-tumourigenic in nude mice (Trainer et al., 1988) and in
our hands the line has a history of poor tumour growth
followed by complete tumour regression after 50-60 days.
WiDr colon adenocarcinoma, however, exhibits a take rate
of 93-100% after about 10 days latency (West et al., 1987).
The lung adenocarcinoma A549 was selected for its longer
latency period (24-25 days), although its take rate remains
high at between 90-93% (Dykes et al., 1989). Finally,
HT1080scc2 human fibrosarcoma was chosen for its variable
growth and lower (50-70%) take rates (Paterson et al.,
1987).
Collagen IV is composed of two different polypeptide
chains which form a triple-helical rod. It constitutes the
structural scaffolding upon which the other membrane com-
ponents are assembled, and prevents the trans-membrane
migration of cells. It is sensitive to degradation by type IV
collagenase (Liotta et al., 1986). Laminin has been found to
exhibit many of the biological effects of matrigel in vitro,
such as promotion of tumour cell adhesion, migration, growth and invasiveness (Martin & Timpl, 1987; Barsky et
al., 1984). Entactin (Nidogen) forms a complex with laminin
and is involved in the binding of laminin to collagen IV
(Timpl, 1989). Subcutaneous (sc) injection of cells with
laminin or collagen type IV has been reported to have no
influence on tumour growth in athymic mice, except in the
case of the highly malignant B16FIO melanoma (Fridman et
al., 1991). We present a further investigation of the effects of
these basement membrane components on tumour xenograft
growth.
It has been shown that metastases of human colorectal
carcinomas can be studied in nude mice and that its outcome
depends upon the metastatic capacity of the cells and the
organ environment of implantation (Giavazzi et al., 1986).
Subcutaneous tumours induced by co-injection of colon car-
cinoma cells with matrigel have been found to consistently
lack any ability to produce metastases from this site, although recently lung colonies resulting from the i.v. injec-
tion of cells isolated from tumours induced by sc co-injection
of NIH3T3 murine cells with matrigel have been observed
(Fridman et al., 1992). The use of intracaecal injection has
provided a more relevant orthotopic site for studying the
process of metastasis in colon cancer (Lin et al., 1991). It has
been suggested that the use of the orthotopic site for co-
implantation with matrigel may result in tumours with meta-
stases (Fridman et al., 1991). We show evidence that matrigel
may enhance the growth ofsuch orthotopic tumours, without
any increase in their metastatic potential.
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Materials and methods
Collagen, laminin, matrigel andfibrin
Matrigel and entactin-free laminin were purchased as isolates
from the EHS mouse tumour (Collaborative Research, Bed-
ford, Mass. USA). Matrigel from the same batch was used in
all experiments, in order to prevent any possible variability in
growth-factor or inhibitor levels. Collagen type IV and
laminin with entactin, isolated from the same source,
together with fibrinogen and thrombin were obtained from
Sigma (Gillingham, Dorset, UK). Laminin and matrigel were
ready-formulated in phosphate-buffered saline (PBS). A solu-
tion of collagen type IV was made by dissolving 1.7 mg in
0.5 ml 0.25% acetic acid in cold PBS, followed by sonication,
mixing and re-buffering to pH 7.0. Fibrinogen and thrombin
were both dissolved in PBS.
Cell cultures
HT1080scc2 human fibrosarcoma cells were obtained from
the Institute of Cancer Research, Chester Beatty Labora-
tories, Fulham Road, London. SW480 and WiDr colon
adenocarcinoma and A549 lung carcinoma cells were obtain-
ed from the American Type Culture Collection (Rockville,
Maryland, USA). SW480 cells were maintained routinely in
Leibovitz medium (L-15), and all other cell lines in Dul-
becco's Modified Eagle's Medium (DMEM). All media were
supplemented with 10% foetal calf serum (FCS) and 1%
penicillin/streptomycin solution containing 10,000 units per
ml. All reagents were obtained from Gibco (Paisley, Scot-
land). The cells were incubated in tissue culture grade plastic
flasks at 37°C. All cells except the SW480 cell line required
5% CO2 in air.
Mice
Four to 8 weeks old male athymic CD1 (nu/nu) mice were
obtained from Charles River (UK) Ltd., and housed in clean
conditions within positive pressure flexible film isolators.
Cellpreparation
After the cells had reached semi-confluence, the medium was
removed and the flasks rinsed with Dulbecco's PBS lacking
Ca2+ and Mg2+. The cells were incubated with a solution of
0.05%trypsin/0.02%versene to release them from the culture
substratum and produce a suspension ofsingle cells. The cells
were resuspended in L-15 or DMEM, followed by a viable
cell number determination by trypan-blue dye exclusion,
centrifugation at +4°C, and re-suspended in cold L-15 or
DMEM. A final density of 1 x 107 cells per ml was obtained
by the addition of a 9:1 volume of either cold liquid matrigel
(2-15mgml-'), collagen IV (3.3mgml-'), laminin (1 mg
ml-') collagen + laminin (3.3 mgml-' and 1 mgml-') enta-
cin-free laminin (1 mgml1'), fibrinogen (12.5mgml-') or
PBS only.
Injection ofcells into mice
Following preparation, 0.1 ml (1 x 106) cells were immedi-
ately injected subcutaneously (sc) with a 23-guage needle into
the right subclavicular region. Generally, 5-10 mice were
used for each group. Cells suspended in fibrinogen were
clotted by the addition of 0.03 ml of 8 mgml-' thrombin
solution per 0.1 ml immediately prior to injection.
For intracaecal implantation, mice were anaesthetised by
intraperitoneal injection of a solution of hypnorm/midaz-
olam. A median incision was then made through the lower
ventral abdominal wall over the region occupied by the
caecum. The caecum was partially exteriorised and a suspen-
sion of 1 x 106 cells in 0.05 ml matrigel or PBS was injected
into the caecal wall. The caecum was then returned to its
normal site, the wound closed and the animal allowed to
recover. After 4 weeks, an exploratory laparotomy was per-
formed to determine interim tumour size. Autopsy and final
tumour measurement was carried out at 8 weeks after im-
plant.
Passage ofxenografts
Tumours initiated from the sc injection of A549 and SW480
cell suspensions with or without matrigel were excised and
1 mm3 fragments implanted sc in nude mice using a trocar.
Tumour measurement andhistology
The growth of tumours was monitored twice weekly by
caliper measurement of tumour length (a) and width (b).
Tumour volume was estimated by using the following for-
mula:
Tumour volume (mm3) = (a + b2)n/6
Experiments were terminated upon or prior to the mean
tumour size reaching 1,000 mm3. Statistical significance was
determined by Student's t test analysis. For histological
examination, slices of tumour were fixed in neutral-buffered
formalin prior to paraffin wax processing and the cutting of
3gtm sections followed by staining with haematoxylin/eosin
(h&e).
Results
Effect ofmatrigel on xenograft growth and tumourigenicity
Co-injection of cells with 10 mgml' matrigel resulted in
significantly increased tumour growth rates and final tumour
volumes over cells injected with medium only, in three out of
the four cell lines under investigation (Figure 1). The growth
rate of SW480 xenografts is normally very slow, the tumours
beginning to regress from day 30, the majority eventually
disappearing after day 50. This tendency was not observed
when SW480 cells were co-injected with matrigel (Figure Ib).
Xenograft growth of the fourth cell line, HT1080SCC2, was
not significantly affected by the addition of matrigel, how-
ever, a marked increase in tumourigenicity, from 50 to 100%,
was observed (Figure Id). There was no significant improve-
ment in tumour size variation within groups when matrigel
was used.
Effect ofpassage on xenografts grown with or without matrigel
1 mm3 fragments of A549 xenografts derived from cells ino-
culated with or without matrigel were washed in PBS prior to
implantation into two groups of five mice. No overall differ-
ence in tumour growth rate between the two groups occurred
(Figure 2).
Similar fragments from SW480 xenografts resulting from
cells co-injected with matrigel, were washed in PBS and
implanted into one group of five mice. No growth of the
implanted fragments occurred.
Effect ofmatrigel concentration on tumour growth
A549 cells were co-injected with a range of matrigel concen-
trations from 12.1 to 1.8 mgml-' into groups each of 5 mice
over two experiments. At a concentration of 1.8 mg ml-l
matrigel, there was no improvement in growth rate compared
to controls. However at 3.6mgml-' growth rate was signifi-
cantly increased (P<0.01). Growth rate continued to in-
crease with increasing matrigel concentration, up to the
highest concentration attainable of 12.1 mgml-' (Figure 3).
Effect ofmatrigel components on xenograft growth,
tumourigenicity andhistology
WiDr cells were co-injected sc into groups each of five mice
with either purified laminin, laminin with entactin, matrigel,
or medium only. The use of either matrigel or purified
laminin resulted in a significant increase in final meanBASEMENT MEMBRANE COMPONENTS AND IN VIVO HUMAN TUMOUR CELL GROWTH 955
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Figure 1 Effect of matrigel on tumour growth of a panel of four cell lines in nude mice, following injection of cells in 0.1 ml
10 mgml- matrigel (-0-) or complete medium (-+-). a, 1 x 106 A549, P<0.02, b, I x I07 SW480, P<0.02, c,
I x 106 WiDr
P<0.001, d, 1 x 106 HT1080scc2 P<0.1. Tumourigenicity was in the range 90-100% with the exception of HT1080scc2 cells
injected in medium only (50%). SW480 tumours resulting from initial inoculations without matrigel regressed from 100% to 30%
tumourigenicity by day 41.
tumour volume compared to that seen when cells were
injected in medium only, whereas laminin with entactin had
no such effect (Figure 4). Histological examination of the
tumours was performed. The control tumours exhibited
monomorphic epithelial-like cells with prominent nucleoli,
arranged in closely packed 'bundles', with a high mitotic
index. The centres of the tumours were highly necrotic.
Tumours from both the purified laminin and the laminin/
entactin groups were essentially the same as the controls, the
stroma between the tumour bundles possibly being more
prominent. Tumours derived from cell suspensions injected
with matrigel however, had a tendency towards a more
'adenoid' and less solid appearance (Figure 5).
Similar results were obtained when A549 cells were used
(not shown). Co-injection of A549 cells with collagen IV, or
a mixture of collagen IV and laminin/entactin did not pro-
duce any increase in tumour growth. A further group of five
mice were given A549 cells co-injected in a weak fibrin clot,
produced by the catalytic conversion of fibrinogen to fibrin
by the addition of thrombin, which thus acted as a non-
matrigel derived substrate control. The use of fibrin did not
increase xenograft growth relative to control growth rates
(data not shown).
Growth oforthotopic tumours by co-injection ofSW480 cells
with matrigel
A group offive mice was injected intracaecally with a suspen-
sion of SW480 cells in 1Omgml' matrigel. A second group
was injected in a similar manner with cells in PBS only. After
8 weeks post implantation the non-matrigel group had not
developed any visible tumours, whereas 100% of the group
of animals given cells with matrigel had developed small
tumours with a mean of 30.4 ± 10.1 (standard error) mg in
the caecal wall. There were no signs of macro- or micro-
metastases in the liver, lungs nor spleen of any of the
tumour-bearing animals.
Discussion
We have demonstrated the tumour-enhancing property of
matrigel for the panel of four cell lines, selected in this study
according to their differing growth characteristics in vivo.
Tumour incidence in all four cell lines was either increased or
maintained at 100% whilst the latency period was reduced.
Tumour growth rate increased in three cell ines. Matrigel was
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Figure 2 Effect of subsequent passage on A549 xenografts
grown with (-0-) or without (-+-) matrigel. P>0.1.
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Figure 3 Effect of matrigel concentration on the growth of A549
cells in nude mice. 1 x 106 cells were co-injected in 0.1 ml matrigel
at 12.1 mgml-' (-m-) P<0.001, 6.1 mgml-' (-A-) P<0.01,
3.57mgml-' (-O-) P<0.01, 1.76 mgml-' (-A-) or medium
only (-+-). 5 animals/group. Tumourigenicity 80-100%.
therefore able to enhance the growth of tumours derived
from cell lines which exhibit either long (A549 and SW480),
or short (WiDr), tumour doubling times. In the light of these
results, we see no obvious reason why matrigel failed to
facilitate an increase in growth rate of the HT1080scc2
derived tumours. However the latter is the only cell line in
the panel which is fibroblastic in origin.
Days post implant
Figure 4 Xenograft growth in nude mice following co-injection
of 1 x 106 WiDr cells with matrigel (-0-), purified laminin
(-X-), laminin with entactin (-O-) or medium only (-+-). Both
matrigel (P<0.001) and purified laminin (P<0.02) significantly
increased tumour growth. 100% tumorigenicity (5 animals/
group).
Published observations have shown that when small cell
lung carcinoma cells, isolated from tumours previously
induced by co-injection with matrigel, are implanted sc,
tumours develop only if these cells are once more trans-
planted in matrigel (Fridman et al., 1991). We report that
when fragments of adenocarcinoma A549 tumours are pas-
saged directly into nude mice, the increased growth rate of
tumours derived from cells co-injected with matrigel is not
maintained. This strongly suggests that the action of matrigel
in tumour growth promotion may not be related to the
selection of a more tumourigenic sub-population of cells, but
to the creation of a more favourable environment for growth.
Examination of stained sections of WiDr and A549
tumours showed that, when grown in the presence of matri-
gel, the cells formed a more differentiated tissue, piling up
around what appeared to be central lumen-like structures
(Figure 5). A similar histological appearance has been
reported for Walker-256 murine breast carcinosarcoma cells
in tumours derived from co-injection with matrigel (Vukic-
evic et al., 1992). No other morphological changes were
observed, apart from those related to the increase in tumour
volume over the control tumours, such as larger areas of
central necrosis and increased vascularisation. Similar growth
characteristics were observed with SW480 cells implanted
intracaecally, where, although an improvement in tumour
growth occurred after co-injection with matrigel, tumour
morphology was identical to that observed in matrigel-
induced sc tumours of this cell line and there were no
observable micro-metastases in the liver or spleen of the host
mice. We recognise that this work concerned with the effects
of matrigel on tumour growth at the orthotopic site is of a
preliminary nature, but we believe it is the first indication of
a possible use for basement membrane products as substrates
for improved orthotopic models of cancer. We have also
observed that improvement in xenograft growth rate is pro-
portional to Matrigel concentration. This confirms the
finding of Fridman et al. (1991) with regard to the dose-
dependent effects of Matrigel on tumour growth, where doses
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Figure 5 Morphology of WiDr adenocarcinoma cells grown with matrigel. Cells formed solid tumours when injected sc in nude
mice (a & b). Co-injection with matrigel resulted in a more glandular morphology (c & d). Bar = 18 ltm.
of matrigel as low as 0.2 mg ml1' Matrigel affected tumour
growth of Bl6FIO melanoma cells. In the present study,
concentrations at least 15 fold higher than this were required
to influence the growth of A549 tumours, a result probably
relating to the different growth characteristics of these two
cell lines.
Growth factors present in entire matrigel may be partly
responsible for these concentration-dependent mitogenic
effects, however it has been observed that these effects also
occur when growth factor free matrigel is used (Fridman et
al., 1991). One possible interpretation of these observations is
that the multi-layered basement membrane-like structure of
the gel, formed by matrigel on reconstitution at 37°C, may
facilitate tumour growth by holding the cells together and
allowing a greater influence on cell growth by autocrine
factors. It has previously been shown that a fibrin clot can
protect human tumour cells from the cytotoxic activity of
natural killer (NK) cells in vitro (Gunji et al., 1988). It is
possible that matrigel may protect implanted cells from the
NK cells present in athymic mice. However, co-injection of
A549 cells in a fibrin-thrombin coagulate did not result in
any improvement in tumour growth over cells injected with
medium only. This suggests that factors other than cellular
protection and initiation of aggregation are involved.
Collagen IV is important in the structural formation of
basement membrane architecture. It forms a highly cross-
linked scaffolding of chords, and in its intact triple-helical
conformation it anchors the laminin/entactin complex, aiding
cell binding (Martin & Timpl, 1987; Timpl, 1989). We found
that when A549 cells were co-injected with collagen type IV,
tumour growth was not increased, suggesting that basement
membrane proteins have specific roles in tumour growth.
Laminin is bound in a high affinity equimolar ratio to
entactin which mediates the binding of laminin to collagen
IV, whereas purified laminin shows no such binding (Aumail-
ley et al., 1989). We have found that co-injection of purified,
entactin-free, laminin significantly increases the growth of
A549 and WiDr tumours, whereas laminin plus entactin has
no such effect (Figure 4). The reasons for these results are
unknown. Previous reports of co-injection with purified lami-
nin have indicated that in most cases it does not enhance
tumour growth, and it has been suggested that this is because
of the highly soluble nature of laminin which renders it
susceptible to degradation in vivo (Fridman et al., 1990).
However, purified laminin has been shown to stimulate cell
proliferation in established cell lines. This activity appears to
originate in domain 1 of the moleculer which is rich in
EGF-like repeats, and it has been suggested that this part of
the molecule may be accessible to cells only during early
stages of tissue development or following injury, where the
basement membrane is either not intact or has been damaged
(Panayotou et al., 1989). Thus the co-injection of cells with
purified laminin may imitate this situation, causing increasing
cell growth, although the situation is a complex one and
other factors such as interaction with host proteins could be
involved.
Our studies indicate that reconstituted basement membrane
can form a basis for improved in vivo models of tumour
growth using cell lines with varied growth characteristics.
Assay systems could be established which utilise reduced
group sizes, greater use of the orthotopic site and relatively
small amounts of matrigel. We have shown that laminin
plays an important part in the growth stimulatory effects of
matrigel in vivo, thus confirming similar effects already
reported for this protein in vitro.
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